![]() The BM group was subdivided into 13 patients in the BM-T group and 10 patients in the BM-not T group. ![]() 24.6 months) did not significantly differ between the two groups. 7.0 months) and overall survival (OS) (21.6 months vs. Median progression-free survival (PFS) (6.5 months vs. No significant differences in patient characteristics were found between the BM and non-BM groups, but proportion of patients with stage IV at diagnosis was significantly higher in the BM group. In addition, the BM group was divided into patients who previously received treatment for BM before pembrolizumab (BM-T group) and those with no prior treatment for BM (BM-not T group).Įighty-seven patients (23 BM group and 64 non-BM group) were assessable for efficacy. Treatment efficacy was compared between patients with (BM group) and without BM (non-BM group). We retrospectively reviewed patients who received pembrolizumab as first-line treatment against NSCLC with PD-L1 TPS ≥ 50 % between March 2017 and September 2019. Therefore, we assessed the efficacy of pembrolizumab against BM of NSCLC with high tumor PD-L1 expression. However, patients with untreated brain metastasis (BM) were excluded from many clinical trials. The KEYNOTE-024 study described the efficacy of pembrolizumab in patients with previously untreated NSCLC who had a PD-L1 TPS of at least 50 %. ![]() Pembrolizumab is recommended for patients with previously untreated non-small cell lung cancer (NSCLC) with a programmed death ligand 1 (PD-L1) tumor proportion score (TPS) of ≥1%.
0 Comments
Leave a Reply. |